Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

August 28, 2026

Study Completion Date

August 28, 2026

Conditions

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG

Sintilimab with P-GEMOX Regimen

Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

DRUG

P-GEMOX Regimen

Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

Trial Locations (1)

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER